MCT Oil and the Aging Brain: What MCI Trials Show

MCTs changed an attention network in a small MCI trial. That is intriguing, not a prescription.

Medium-chain triglycerides (MCTs) reliably raise blood ketones, which can provide the brain with an alternative fuel source. The more interesting question is whether that metabolic shift changes how people think—or how their brains function.

A six-month randomized trial offers an unusually detailed clue. In 32 people with mild cognitive impairment (MCI), ketogenic MCT supplementation changed measures of energy use, functional connectivity, and white-matter fiber density within the dorsal attention network, a brain system involved in directing attention. The results are more specific than the usual supplement-study promise of feeling "mentally sharp." They are also preliminary: 17 participants received ketogenic MCTs and 15 received placebo.

The evidence supports cautious interest in MCTs as an adjunct for some people with MCI. It does not show that MCT oil prevents dementia, reverses brain aging, or works equally well for everyone.

What the brain-imaging trial found

In the double-blind BENEFIC trial reported by Roy et al., researchers combined three imaging methods in participants with MCI: ¹¹C-acetoacetate PET to measure brain ketone uptake, resting-state fMRI to assess network connectivity, and diffusion MRI to measure white-matter microstructure.

Compared with placebo, ketogenic MCT supplementation increased ketone uptake in cortical regions of the dorsal attention network. Greater regional ketone uptake correlated with improved resting-state functional connectivity in that same network. Diffusion MRI also showed increased fiber density within its structural connectome, and improvements in network connectivity co-varied with performance on attention-focused cognitive tests.

That sequence is biologically coherent: MCTs raise ketones; the brain takes up more ketones in relevant regions; network measures shift alongside attention performance. But correlation within a trial does not prove each link causes the next. Diffusion MRI cannot identify the tissue change directly, so "increased fiber density" is accurate; claims of confirmed new axons or wholesale brain rewiring are not.

The study's size is its main constraint. With 32 participants, it cannot provide a reliable clinical effect estimate, settle whether APOE genotype changes the response, or establish that the imaging changes reduce progression to dementia.

A larger trial found modest cognitive improvements—but no clear combination advantage

A 12-month double-blind, placebo-controlled trial by Duan et al. tested MCTs, DHA, their combination, and placebo in 280 Chinese older adults with MCI, with 70 participants per group. The MCT group received 24 g per day of C8 plus C10 MCTs; the DHA group received 800 mg per day; and the combination group received both.

All three active treatments significantly improved full-scale IQ versus placebo. The reported estimates were β=0.107 (95% CI, 0.006 to 0.208) for MCTs, β=0.135 (95% CI, 0.034 to 0.235) for DHA, and β=0.136 (95% CI, 0.035 to 0.237) for MCTs plus DHA.

The metabolic results followed expectations: circulating ketones rose most with MCT plus DHA, then MCTs alone, with the smallest increase in the DHA group. Yet the IQ estimates were similar across the three active arms. All also reduced plasma Aβ42 and mitochondrial DNA-deletion markers relative to placebo, with comparable effects across groups.

This pattern complicates a simple "more ketones, more cognition" story. DHA may contribute through mechanisms separate from ketogenesis, and a 2024 meta-analysis by Chang et al. found statistically significant but modest cognitive improvements from omega-3 fatty acids in MCI. The trial did not show that combining DHA with MCTs produced a meaningful cognitive advantage over either alone, even though the combination produced the largest ketone increase.

Its biomarker findings also remain biomarkers. Lower plasma Aβ42 or fewer mitochondrial DNA deletions do not demonstrate slower cognitive decline, lower dementia incidence, or better quality of life.

Ketones rise consistently; cognition does not

The clearest consensus comes from a 2023 systematic review and meta-analysis by Castro et al., which examined 17 studies across subjective cognitive decline, MCI, and Alzheimer's disease. All 12 studies that measured ketones found a significant increase after medium-chain fatty-acid supplementation. MCTs do the fuel-delivery job.

Cognitive findings were much less consistent. Eight of 13 studies reported cognitive improvement, while four found no improvement despite increased ketones. Two studies found benefits only in people who did not carry the APOE ε4 variant. This matters because APOE ε4 is the major genetic risk factor for Alzheimer's disease, yet it may identify people least likely to benefit cognitively from MCTs.

The review searched through January 2021, so it did not include the BENEFIC neuroimaging analysis or the 2025 Duan trial. Even so, its central warning still holds: raising ketones appears necessary for an MCT effect, but it is not sufficient to guarantee a cognitive effect.

Healthy aging is a weaker use case

MCT marketing often targets healthy older adults seeking prevention. The evidence there is thinner than the marketing copy. A 2022 systematic review by Giannos et al. found only six randomized trials in non-demented older adults. The direction of results favored memory improvement, but the authors could not pool them because the studies differed too much in dose, duration, outcome measures, administration, and blinding.

Doses ranged from 6 to 40 g per day, and intervention periods ran from a single occasion of less than 10 days to three months. Four trials were double-blind and two were single-blind. Those are not minor variations on one tested protocol; they are materially different interventions. No reliable effect size or optimal dose exists for cognitively healthy adults.

Where MCTs fit beside exercise

MCTs should not displace the basics with better evidence. A 2022 meta-analysis of 12 randomized trials found cognitive benefits from exercise training in adults over 60 with MCI, including aerobic, resistance, and multimodal programs. A 2025 network meta-analysis likewise evaluated exercise types, frequency, and duration for cognitive health in older adults.

One large exercise trial illustrates why even this stronger literature needs careful reading. In the 18-month EXERT trial, 296 sedentary older adults with amnestic MCI were assigned to moderate-to-high-intensity aerobic exercise or low-intensity stretching, balance, and range-of-motion work. The groups did not differ on the global cognitive composite (regression estimate -0.078, standard error 0.074; p=0.3). The broader exercise evidence is more extensive and replicable than the MCT evidence, but no single trial settles the question.

A practical, appropriately modest verdict

For a person with MCI who wants to try MCTs, the best-supported formulation is dedicated C8 plus C10 MCT oil, not coconut oil. The largest trial used 24 g per day. Coconut oil contains substantial lauric acid and does not match the C8/C10 intervention or its ketone response.

Starting near 5 g per day and increasing gradually is sensible because higher doses can cause nausea or diarrhea. However, the accessible reports of the key trials do not provide the adverse-event rates, dropout data, or dose-escalation details needed to quantify tolerability at 24 g per day.

MCTs have a credible metabolic effect and early MCI evidence that includes modest cognitive improvements and a small, sophisticated brain-imaging trial. They have not earned claims of dementia prevention or universal cognitive benefit.

The most defensible candidates are people with MCI, particularly APOE ε4 non-carriers, who view MCTs as an add-on to exercise, sleep, cardiovascular risk management, and clinical care. For healthy older adults and APOE ε4 carriers, the evidence supports curiosity and careful expectations—not a confident recommendation.